Anixa Biosciences Receives Notice of Allowance from Korean Ministry of Intellectual Property (MOIP) for Patent Covering Breast Cancer Vaccine Technology
MWN-AI** Summary
Anixa Biosciences, Inc., a prominent biotechnology company focused on cancer treatment and prevention, has received a Notice of Allowance from the Korean Ministry of Intellectual Property (MOIP) for its breast cancer vaccine technology patent. This significant milestone expands Anixa's intellectual property portfolio, providing exclusive protection for their innovative approach to breast cancer treatment in South Korea, where the incidence of breast cancer has been notably rising among younger women.
The newly allowed patent, titled "Vaccine Adjuvants and Formulations," is co-invented by Dr. Justin Johnson and the late Dr. Vincent Tuohy of the Cleveland Clinic. This patent reinforces Anixa’s standing within the global cancer immunotherapy field, following similar patents issued in the United States and other international markets. The development comes at a critical time, as breast cancer remains the most frequently diagnosed cancer in women worldwide, with no approved preventive vaccines currently available.
Dr. Amit Kumar, the Chairman and CEO of Anixa, emphasized the patent's role in broadening international recognition of their vaccine's potential. Recent clinical trials at Cleveland Clinic showed promising results, with the vaccine being well-tolerated and generating immune responses in 74% of participants, paving the way for further clinical development.
Anixa's vaccine aims to induce immunity against human ?-lactalbumin, a protein related to lactation that is expressed in certain breast cancer types. The strategy seeks to prime the immune system for tumor prevention while protecting healthy tissues, particularly regarding aggressive forms like triple-negative breast cancer. With its growing patent estate, Anixa is establishing a framework for future global collaborations and commercialization of its groundbreaking technologies.
MWN-AI** Analysis
Anixa Biosciences (NASDAQ: ANIX) has recently received a Notice of Allowance from the Korean Ministry of Intellectual Property for a patent covering its innovative breast cancer vaccine technology. This development is a strategic milestone for Anixa, as it expands its global intellectual property portfolio, bolstering its competitive edge in the oncology space where breast cancer rates are rising, particularly among younger women.
The patent license, sourced from Cleveland Clinic, safeguards the vaccine's composition and establishes Anixa’s presence in South Korea, a rapidly growing market for breast cancer treatments. Given the increasing incidence of breast cancer in the region, combined with the absence of preventative vaccines for this disease, Anixa’s technology holds significant potential for market penetration and sales growth.
Moreover, the company’s progress in clinical trials—with promising immune responses observed—augments the validity of this patented technology, thereby attracting interest from larger pharmaceutical firms for potential partnership and commercialization opportunities. As Anixa continues its clinical development in the U.S. and solidifies its position as a leader in cancer immunotherapy, stakeholders should consider the implications of this patent allowance on Anixa’s valuation and future performance.
Investors should closely monitor the company’s clinical trials and potential regulatory approvals, as these will have substantial impacts on share price. Additionally, exploring partnerships for global commercialization is a pivotal strategy that could enhance revenue streams significantly.
In summary, Anixa's recent patent allowance not only reinforces its innovative capabilities but also positions the company strategically for future growth in a lucrative market. As always, potential investors should weigh the risks involved, including competition and regulatory challenges, while considering Anixa as an emerging player in the biopharmaceutical landscape.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
Notice of Allowance marks first Korean patent covering Anixa's breast cancer vaccine platform
Expands global intellectual property coverage in markets with increasing breast cancer incidence rates and greater concentrations of younger breast cancer patients
SAN JOSE, Calif., March 9, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the Korean Ministry of Intellectual Property (MOIP) has issued a Notice of Allowance for a new patent related to Anixa's breast cancer vaccine technology. This patent, exclusively licensed from Cleveland Clinic, will provide composition of matter protection for the Company's novel approach to breast cancer treatment and prevention in South Korea. The patent is titled, "Vaccine Adjuvants and Formulations," and the co-inventors are Dr. Justin Johnson and the late Dr. Vincent Tuohy, both of Cleveland Clinic.
With this allowance, Anixa continues to expand the international scope of its intellectual property portfolio, reinforcing its leadership in the field of cancer immunotherapy. The Korean patent complements patents issued in the United States and other key global jurisdictions, and represents an important step toward potential future regulatory approvals and commercialization efforts outside the United States.
"This newly allowed patent continues the broad international recognition of the novelty and potential of our breast cancer vaccine," stated Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences. "As we continue clinical development in the U.S., our growing international patent estate further strengthens our ability to pursue global opportunities and potentially partner with larger pharmaceutical companies for worldwide commercialization. In our recently completed Phase 1 clinical trial conducted at Cleveland Clinic, the vaccine met all major primary endpoints, was safe and well tolerated, and generated immune responses in 74% of participants, supporting continued clinical development of this novel preventive approach."
While the breast cancer survival rate is high in South Korea, the incidence rate has been increasing rapidly. In addition, unlike Western nations, the onset of breast cancer tends to occur earlier in life in South Korea. Breast cancer remains the most commonly diagnosed cancer among women worldwide, and currently there are no approved vaccines to prevent the disease.
Anixa's vaccine is based on immunizing against human ?-lactalbumin, a protein associated with lactation that is aberrantly expressed in certain types of breast cancer. This "retired" protein strategy, developed at Cleveland Clinic and licensed exclusively to Anixa, aims to selectively prime the immune system to prevent tumor formation while avoiding harm to normal tissue, particularly in aggressive forms of the disease such as triple-negative breast cancer.
By reinforcing its global patent estate, Anixa is laying the groundwork for future international development and commercialization strategies. The Company's broader vaccine platform also targets other high-incidence cancers and is designed to transform how the medical community approaches cancer prevention. If successful, the technology could represent one of the first preventive vaccine approaches targeting breast cancer.
About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of liraltagene autoleucel, or lira-cel, an ovarian cancer immunotherapy being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. This technology is differentiated from other cell therapies as the natural ligand of the FSHR receptor, FSH, binds to the FSHR receptor on the tumor cell instead of an antibody fragment. Moffitt is a world leader in cancer immunotherapy treatments, pioneering next-generation cell therapies such as CAR-T, and tumor infiltrating lymphocytes (TILs) to harness the power of the immune system. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. The breast and ovarian cancer vaccines were developed at Cleveland Clinic and exclusively licensed to Anixa. Cleveland Clinic is entitled to royalties and other commercialization revenues from the Company related to these vaccine technologies. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on LinkedIn, X, Facebook and YouTube.
Forward-Looking Statements
Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.
Contact:
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808
SOURCE Anixa Biosciences, Inc.
FAQ**
How does the recent Notice of Allowance from the Korean Ministry of Intellectual Property enhance Anixa Biosciences Inc. ANIX's strategic position in the global breast cancer vaccine market, particularly in light of rising incidence rates in South Korea?
What specific benefits or competitive advantages does the allowed patent provide to Anixa Biosciences Inc. ANIX in the commercialization process of its breast cancer vaccine technology within international markets?
Given that clinical trials have shown promising results for Anixa Biosciences Inc. ANIX's breast cancer vaccine, what are the next steps in terms of regulatory approvals and partnerships with larger pharmaceutical companies for further development?
How does the integrated approach of immunizing against retired proteins in Anixa Biosciences Inc. ANIX's breast cancer vaccine potentially differentiate it from other cancer prevention technologies currently in development?
**MWN-AI FAQ is based on asking OpenAI questions about Anixa Biosciences Inc. (NASDAQ: ANIX).
NASDAQ: ANIX
ANIX Trading
-2.16% G/L:
$2.945 Last:
14,543 Volume:
$2.98 Open:
